Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs1.73 B1.95 B2 B2.02 B2.23 B2.22 B2.22 BRecherche et développement———————Résultat d'exploitation2.45 B3.26 B1.77 B725.6 M1.09 B1.38 B1.44 BTotal des produits hors exploitation-226.3 M52.6 M-16.5 M44.1 M82.3 M-40 M-46.4 MCharges d'intérêts, nettes des intérêts capitalisés207.4 M212.1 M180.3 M199.6 M208.3 M224.1 M223.2 MRésultat hors exploitation, hors charges d'intérêts-401.6 M-202 M-171.5 M-171 M-186.2 M-209.1 M-202.5 MRevenus/dépenses exceptionnels-32.1 M42.5 M-25.3 M15.5 M60.2 M-55 M-67.1 MRésultat avant impôts2.22 B3.15 B1.59 B567.5 M958.1 M1.09 B9.82 BPart des actionnaires dans le résultat2.9 M26.5 M5.4 M-1.4 M-1.4 M-13.3 M-18.1 MImpôts662.1 M747.1 M302 M188.5 M212.4 M229.8 M209.3 MIntérêts ne donnant pas le contrôle / intérêts minoritaires900 K2.2 M1.5 M1.2 M1.1 M1.2 M1.2 MAutres produits/charges après impôts———————Résultat net avant activités abandonnées1.56 B2.38 B1.28 B379.2 M746 M876.5 M941.5 MActivités abandonnées———38.8 M00—Résultat net1.56 B2.38 B1.28 B418 M746 M876.5 M941.5 MAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires1.56 B2.38 B1.28 B418 M746 M876.5 M941.5 MBénéfice par action de base (BPA de base)13.7421.1312.074.88.8910.5411.37Bénéfice par action dilué (BPA dilué)13.6420.95124.778.8410.4611.29Nombre moyen d'actions de base en circulation113.26 M112.56 M106.04 M87.1 M83.9 M83.2 M—Nombre d'actions en circulation après dilution114.07 M113.49 M106.62 M87.6 M84.4 M83.8 M—EBITDA3.02 B3.97 B2.35 B1.28 B1.71 B2.14 B2.05 BEBIT2.37 B3.21 B1.72 B705.6 M1.07 B1.46 B1.36 BCoût des ventes9.03 B10.5 B10.49 B8.8 B9.38 B9.94 B10.07 BAutres coûts des ventes———————Amortissements (flux de trésorerie)624.7 M745.1 M633.9 M577.3 M643.5 M681.1 M687.6 M
Labcorp Holdings Inc. Common Stock
Labcorp Holdings Inc., operating under the brand name Labcorp, headquartered in Burlington, North Carolina, provides laboratory services used for diagnosis and healthcare decisions. It operates one of the largest clinical laboratory networks in the world and has operations in over 100 countries; although its operations are primarily in the U.S.
Its Diagnostics Laboratories segment operates 2,000 patient service centers with more than 6,000 in-office phlebotomists in the United States. In addition to healthcare testing such as oncology testing, human immunodeficiency virus genotyping and phenotyping, it provides testing for: employment, DNA testing to determine parentage and to determine immigration eligibility, environmental issues, wellness, toxicology, pain management, and medical drug monitoring. It also provides 50 tests that patients can complete at home. It processes over 160 million tests per year. Approximately 10% of this segment’s revenue are from the U.S. Medicare health insurance program.